These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 32354888)
1. Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP Katsuya Y; Miyake K; Higuchi T; Oshiro H; Sugisawa N; Singh SR; Goto Y; Zhao M; Hoffman RM In Vivo; 2020; 34(3):1027-1030. PubMed ID: 32354888 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396 [TBL] [Abstract][Full Text] [Related]
3. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498 [TBL] [Abstract][Full Text] [Related]
4. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
5. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341 [TBL] [Abstract][Full Text] [Related]
6. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260 [TBL] [Abstract][Full Text] [Related]
7. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer. Lu Y; Bian D; Zhang X; Zhang H; Zhu Z Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796 [TBL] [Abstract][Full Text] [Related]
10. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930 [TBL] [Abstract][Full Text] [Related]
11. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353 [TBL] [Abstract][Full Text] [Related]
12. AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1. Zhao R; Yin W; Yu Q; Mao Y; Deng Q; Zhang K; Ma S Bioengineered; 2022 Jan; 13(1):331-344. PubMed ID: 34738874 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer. Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia. Khoo T; Gao L Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783 [No Abstract] [Full Text] [Related]
16. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Nakamura R; Yamada T; Tokuda S; Morimoto K; Katayama Y; Matsui Y; Hirai S; Ishida M; Kawachi H; Sawada R; Tachibana Y; Osoegawa A; Horinaka M; Sakai T; Yasuhiro T; Kozaki R; Yano S; Takayama K Cancer Lett; 2024 Aug; 598():217124. PubMed ID: 39059573 [TBL] [Abstract][Full Text] [Related]
17. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722 [TBL] [Abstract][Full Text] [Related]
18. Mixed response to osimertinib and the beneficial effects of additional local therapy. Shinno Y; Goto Y; Sato J; Morita R; Matsumoto Y; Murakami S; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2019 Apr; 10(4):738-743. PubMed ID: 30735003 [TBL] [Abstract][Full Text] [Related]
19. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Nishiyama A; Takeuchi S; Adachi Y; Otani S; Tanimoto A; Sasaki M; Matsumoto S; Goto K; Yano S Cancer Sci; 2020 Oct; 111(10):3813-3823. PubMed ID: 32735723 [TBL] [Abstract][Full Text] [Related]
20. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]